|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Dose** | **CEA status** | **ID** | **Sum of all lesions volume** **(cm3)** | **Indication** |
| 6mg | + | 6027 | 52.48 | Rectal cancer |
| 6001 | 16.20 | CRC |
| 6003 | 27.80 | Colon cancer |
| 6005 | 101.83 | Rectal cancer + NSCLC |
| 30 mg | + | 6028 | 76.5 | Rectal cancer |
| 6004 | 78.6 | Sigmoid cancer |
| 6007 | 214.48 | NSCLC |
| 6008 | 32.5 | NSCLC |
| 6 mg | - | 6023 | 112.32 | Pancreatic cancer |
| 6026 | 21.25 | RCC |
| 6002 | 12.70 | Melanoma |
| 30 mg | - | 6006 | 101.40 | Ovarian cancer |
| 6009 | 84.60 | RCC |
| 6010 | 161.80 | Melanoma |
| 20 mg | +  | 6031 | 52.2 | CRC |
| 20 mg | + | 6033\* | 24.2 | CRC |
| Data from patients 6031 and 6033 were used as external dataset for the uptake tumor model validation.\*Patient 6033 also has tumor uptake assessment at cycle 4 (see Figure 3 bottom right) |